Two-time Oscar-winning Iranian director Asghar Farhadi has called on artists and filmmakers around the world to protest against the U.S. and Israel’s bombing of Iran to “prevent the destruction of ...

The two-time Oscar-winning Iranian director raised the alarm on "destructive aggression" in his country amid the U.S.-Iran war. By Etan Vlessing Canada Bureau Chief Two-time Oscar-winning Iranian ...

Veteran Iranian filmmaker Asghar Farhadi has asked his fellow filmmakers and artists to speak publicly in opposition to what he described as the “destructive aggression” of the current war between the ...

I am honored to stand for election as president-elect of ALA. My career has been shaped by a profound belief in the power of libraries to advance equity, expand opportunity, and strengthen our ...

The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

Humira (adalimumab) is a biologic medication used to treat several chronic inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and plaque psoriasis. For years, it has been one of ...

Humira (adalimumab) is a prescription drug that treats certain inflammatory conditions. Its works by blocking the TNF protein, which reduces inflammation and pain. The effectiveness of this drug may ...

Amjevita and Imraldi, two biosimilar agents for adalimumab (Humira), were just as effective in treating psoriasis as the original drug for both new users and patients who switched from adalimumab to ...

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...

Humira (adalimumab) and Remicade (infliximab) are prescription drugs used to treat certain inflammatory conditions. Humira is given as an injection, while Remicade is given as an infusion. Humira and ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- and low-concentration (40 mg/0.4 ml, 40 mg/0.8 ml) autoinjectors and ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...